High dose multiple micronutrient supplementation improves villous morphology in environmental enteropathy without HIV enteropathy: results from a double-blind randomised placebo controlled trial in Zambian adults. by Louis-Auguste, John et al.
Louis-Auguste, J; Greenwald, S; Simuyandi, M; Soko, R; Banda, R;
Kelly, P (2014) High dose multiple micronutrient supplementation
improves villous morphology in environmental enteropathy without
HIV enteropathy: results from a double-blind randomised placebo
controlled trial in Zambian adults. BMC Gastroenterol, 14 (1). p.
15. ISSN 1471-230X DOI: 10.1186/1471-230X-14-15
Downloaded from: http://researchonline.lshtm.ac.uk/1472244/
DOI: 10.1186/1471-230X-14-15
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
RESEARCH ARTICLE Open Access
High dose multiple micronutrient supplementation
improves villous morphology in environmental
enteropathy without HIV enteropathy: results from
a double-blind randomised placebo controlled trial
in Zambian adults
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Abstract
Background: Environmental enteropathy (EE) is an asymptomatic abnormality of small bowel structure and
function, which may underlie vaccine inefficacy in the developing world. HIV infection co-exists in many of these
populations. There is currently no effective treatment. We conducted a secondary analysis of a randomised
controlled trial of high dose multiple micronutrient (MM) supplementation on small bowel architecture in EE in
participants with or without HIV infection.
Methods: In a double-blind parallel-group trial of the effect of MM on innate immune responses to oral vaccines,
consenting Zambian adults were randomised to receive 6 weeks of 24 micronutrients as a daily capsule or placebo.
HIV status was established after randomisation. Proximal jejunal biopsies were obtained after the supplementation
period. Villous height, crypt depth, villous width, villous perimeter per 100 μm muscularis mucosa (a measure of
epithelial surface area), and villous cross sectional area per 100 μm muscularis mucosa (a measure of villous
compartment volume) were measured in orientated biopsy sections using semi-automated image analysis.
Analysis was by intention to treat.
Results: 18 patients received MM and 20 placebo. 6/18 MM and 9/20 placebo patients had HIV. In HIV negative
patients given MM compared to placebo, mean villous height was 24.0% greater (293.3 v. 236.6 μm; 95% CI of
difference 17.7–95.9 μm; P = 0.006), mean villous area was 27.6% greater (27623 v. 21650 μm2/100 μm; 95% CI of
difference 818–11130 μm2/100 μm; P = 0.03), and median villous perimeter was 29.7% greater (355.0 v. 273.7 μm/
100 μm; 95% CI of difference 16.3–146.2 μm/100 μm; P = 0.003). There was no significant effect on crypt depth or
villous width. No effect was observed in HIV positive patients. There were no adverse events attributable to MM.
Conclusions: MM improved small bowel villous height and absorptive area, but not crypt depth, in adults with
EE without HIV. Nutritional intervention may therefore selectively influence villous compartment remodelling.
In this small study, there was a clear difference in response depending on HIV status, suggesting that EE with
superimposed HIV enteropathy may be a distinct pathophysiological condition.
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Background
Environmental enteropathy (EE) is an asymptomatic
disorder which is highly prevalent throughout the devel-
oping world. It is thought to be the result of recurrent
exposure to gastrointestinal pathogens [1], but could be
explained by other factors including nutrient deficien-
cies. It is characterised by abnormal villous and crypt
architecture, heightened T cell-mediated inflammation and
increased epithelial permeability secondary to impaired
tight junction function [2,3] which results in reduced small
bowel absorptive capacity, increased microbial transloca-
tion and systemic inflammation [4]. This predisposes to
poor growth in children [4] and malabsorption in people
of all ages. Furthermore, although live oral vaccines against
a number of enteric viral and bacterial pathogens including
rotavirus and Salmonella Typhi/Paratyphi provide high
rates of effective immunity in Western populations, their
efficacy in low income countries is markedly reduced [5]
which compromises their potential as effective public
health interventions. Populations with reduced vaccine effi-
cacy have a high prevalence of environmental enteropathy
(EE) [2,6]. From an immunological perspective, chronic
immune stimulation can lead to suppressed immune re-
sponse to pathogenic bacteria and may therefore explain
the reduced immunogenicity of oral vaccines in these
populations. EE is therefore increasingly recognised as
being of critical importance in global health [1].
HIV co-exists with EE in many populations, particu-
larly in sub-Saharan Africa. We have observed that this
results in an asymptomatic HIV-associated enteropathy
that has subtle histological and functional differences
from EE in HIV negative patients. For example com-
pared to HIV negative patients, EE with HIV is charac-
terised by more marked crypt hypertrophy and intestinal
permeability. Villous height is also correlated with CD4
count [2,6]. This is distinct from the 'HIV enteropathy'
used by some authorities to refer to a clinical condition
seen in advanced HIV where no causative pathogen is
readily identified, characterised by persistent diarrhoea,
more severe morphological changes and marked malab-
sorption. The intestinal mucosal immune system is affected
early and significantly in HIV infection [7], and effector T
cell dysfunction may explain the exaggerated inflammation
and impaired gut barrier function seen in early asymptom-
atic disease [2].
There is no established therapy to reverse the changes
of EE. Antibiotics [8], probiotics [9], glutamine supple-
mentation [10] and long chain fatty acid supplements
[11] have been tried without success. Multiple micronu-
trient (MM) supplementation is an attractive potential
therapy as micronutrients such as zinc [12,13] and
vitamin A [14] have previously been shown to reduce
morbidity and mortality from infectious diarrhoeal
illnesses, hinting at an immunological role in the intestine.
Furthermore, populations in which EE is prevalent also
have a high prevalence of micronutrient deficiencies,
which is also seen in HIV positive individuals. MM
supplementation is also practical due to its low cost, ease
of administration, tolerability and safety profile.
There are few data on MM interventions for EE, but
in our own previously published trials, long-term lower-
dose MM supplementation had a modest impact on
diarrhoea and nutritional outcomes, and some effect on
antimicrobial peptide expression [12,15]. Similarly, little
is known about the role of MM supplementation in HIV
patients [16], although several micronutrient deficiencies
have been shown to be associated with worse outcomes
[17]. Vitamin A and zinc supplementation is beneficial,
at least in children [18]. Our study [12] demonstrated a
reduction in HIV-related deaths with an MM supple-
ment, and a recent trial of 3 vitamins with selenium
showed a significant reduced disease progression and
HIV-related death [19], again hinting at a role for enteral
micronutrient supplementation in enhancing mucosal
and systemic immunological function.
We have also shown that lower micronutrient doses
did not reliably increase the concentrations of the
micronutrients in blood [12]. While this might signify
that these nutrients were being redistributed or utilised,
it might also reflect the very malabsorptive problem
which we are trying to overcome. We postulated that
micronutrient supplementation at higher doses than
used in our previous trial might improve mucosal archi-
tecture in patients with EE.
Methods
Trial design and study setting
This was a secondary study of endoscopic small bowel
biopsies obtained during the course of a single centre,
randomised, double-blind, placebo-controlled, parallel-
group trial investigating the effect of high dose MM
supplementation on innate immune effects of oral
vaccines. This was carried out in adult volunteers living
in a poor community in Lusaka, Zambia between June
and October 2009, where we have demonstrated that EE
is virtually universal [2].
Participants
Volunteers were recruited from among residents of
Misisi suburb, where we have carried out several previ-
ous studies of intestinal inflammation. Age between
18 and 60 years was the only inclusion criterion. The
only absolute exclusion criterion was helminth infection
(diagnosed by stool microscopy at screening). Participants
who were pregnant, lactating, had had vaccination within
6 months, had taken antibiotics or non-steroidal anti-
inflammatory drugs within two weeks, or who had had
diarrhoea within one month were not included in any part
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of the study until their temporary exclusion criterion no
longer applied. Informed consent followed a three stage
process: door-to-door notification, focus group discus-
sions, and individual counselling leading to fully informed
written consent.
Micronutrient supplementation, treatment allocation, and
randomisation
The composition of the multiple micronutrient supple-
ment (Immunace®, Vitabiotics, London, UK) is shown in
Table 1, together with dosages of the supplement used
in our earlier study [12]. The supplement was chosen to
provide micronutrients at higher dosages than in the
earlier study with the exception of iron (due to concerns
of poorer outcome in malaria with iron [20]) and copper
(due to theoretical concern of long-term toxicity). An
indistinguishable placebo was manufactured and packaged
in identical plastic light-proof bottles. The bottles were
labelled only with a letter of the 4-letter code (two letters
representing MM and the other two representing placebo)
held by the manufacturer until morphometric analysis had
been completed, when the databases had been locked.
Participants were randomised to one of these 4 letters
using a computer-generated sequence in a 1:1:1:1 ratio.
Treatment allocation was therefore masked from par-
ticipants and investigators throughout the duration of
the study.
Interventions
Participants were provided with a six week supply of
once-daily trial medication and given instructions on
how to take it (days 1 – 42). After the supplementation
period they underwent enteroscopy with proximal jejunal
biopsy under conscious sedation (performed by PK) on
day 43. Patients were then vaccinated with a full course of
Ty21a oral typhoid vaccine (Vivotif ®, Crucell, Baranzate,
Italy; 3 doses on days 44, 46 and 48), and were re-biopsied
14 days later (Figure 1). Unvaccinated patients were also
included as negative controls for analysis of vaccination
effects, and only underwent endoscopic biopsy once (after
the 6 week supplementation/placebo period).
Serological HIV testing was conducted on all partici-
pants prior to vaccination after appropriate counselling.
Table 1 Composition of micronutrient supplement
compared to Reference Nutrient Intake (RNI) for British
adults (men or women, whichever is the higher) [21]
Micronutrient Daily dose Daily dose
in 2008
study
RNI Multiples
of RNI in
current study
Vitamin A
Retinyl palmitate
(mg)
1.6 (4840 i.u.) - 0.7 2.3
Betacarotene (mg) 6.0 4.8 4.2 1.4
Vitamin D (μg) 20 5 10a 2
Vitamin E (mg) 80 10 4 20
Vitamin K (μg) 140 - 1/kg/d 2
Vitamin C (mg) 300 70 40 7.5
B vitamins
Thiamin (B1) (mg) 36 1.4 0.9 40
Riboflavin (B2) (mg) 12 1.4 1.3 9.2
Pyridoxine (B6) (mg) 20 1.9 1.4 14.2
Niacin (B3) (mg) 54 18 16 3.4
Folic acid (B9) (mg) 1 0.4 0.2 5
Cobalamin (B12) (μg) 28 - 1.5 18.7
Pantothenic acid
(B5) (mg)
40 - 5b 8
Minerals
Iron (mg) 16 30 14.8 1.08
Zinc (mg) 30 15 9.5 3.2
Copper (mg) 1 2 1.2 0.83
Selenium (μg) 350 65 75 4.7
Iodine (μg) 400 150 140 2.9
Chromium (μg) 200 - 25b 8
Magnesium (μg)c 100 - 250 0.4
Manganese (mg) 8 - 1.4b 5.7
L-Cystine (mg) 80 - - -
L-Carnitine (mg) 60 - - -
Citrus bioflavonoids
(mg)
60 - - -
aBased on RNI for older adults; no intake of pre-formed vitamin D is required
for adults exposed to sun. bNot a formal RNI but probably an adequate intake.
cFull dose RNI of Magnesium cannot be administered in this form as it may
predispose to diarrhea.
Figure 1 Study outline.
Louis-Auguste et al. BMC Gastroenterology 2014, 14:15 Page 3 of 10
http://www.biomedcentral.com/1471-230X/14/15
Patients who were found to be HIV positive were re-
ferred for further assessment, treatment and monitoring.
Participants were interviewed at monthly intervals to
check for possible side effects, illnesses, and promote
compliance with trial medication. Participants were also
directly asked about incidence of diarrhoea, abdominal
pain, fever, loss of appetite and nausea/vomiting.
Morphometric analysis
This was performed as previously described [2]. Briefly,
endoscopic small intestinal biopsies were orientated
under the dissecting microscope before formalin fixation
and paraffin embedding. 4 μm sections were stained with
haematoxylin & eosin as per standard protocols. Stained
sections were first assessed for adequacy of orientation
by a single investigator blinded to treatment allocation
(JL-A), where both crypts and villi were seen in longitu-
dinal section. Adequately orientated sections were then
digitised using a Zeiss Axiocam digital camera system
(Carl Zeiss Vision, Thornwood, NY). Images were ana-
lysed by the same investigator using a semi-automated
program (written by SEG, modified from the previously de-
scribed macro [2]; Additional file 1; also available at http://
webspace.qmul.ac.uk/segreenwald/KS400%20macro.pdf )
using a Zeiss KS400 v.33.0 image analysis system (Carl
Zeiss Vision, Thornwood, NY). Maximal villous height
(VH), maximal villous width perpendicular to the VH axis
(VW), and crypt depth (CD) were measured, along with
villous perimeter (VP) as a measure of epithelial surface
area, and villous cross sectional area (VA) as a measure of
villous compartment volume (Figure 2). VP and VA were
expressed per 100 μm muscularis mucosae.
Sample size, power calculations and statistical analysis
Analysis was by intention to treat. This was a secondary
analysis of a study which was primarily powered to
detect differences in antimicrobial peptide expression
following vaccination.
Based on the morphometry results from our previous
study of enteropathy in the same patient population [2],
we estimated that 15 patients per treatment group would
have greater than 80% power to identify a 20% difference
in villous height at a 2-sided α of 0.05. We would expect
a significant improvement in villous height (20% or
greater) to result in clinically significant improvements
in absorptive capacity and mucosal physiology. A post
hoc power analysis in HIV positive patients showed that
6 patients would be needed to detect a difference of
at least 24% (equivalent to 65 μm) in villous height
(SD 36.3; 2-sided α 0.05; power 0.8).
Although VH, CD and VA were normally distributed,
VP and VW were not (Shapiro-Wilk test). Two-tailed t-
or paired t-tests were used for normally distributed
data. Wilcoxon signed rank (for paired observations)
or Kruskal-Wallis (for independent observations) tests
were used for non-parametric data. Spearman correl-
ation coefficients were used where required. Where
both pre- and post-vaccination data were available,
analysis was performed using either only pre- or only
post-vaccination biopsy measurements. The most con-
servative results are presented here.
Statistics were calculated using SPSS v.21 (IBM
Corporation, Armonk, New York, USA) and Stata v.12
(StataCorp LP, College Station, Texas, USA).
Outcomes
This study was a secondary analysis. The primary
comparison for this study was the difference in morpho-
metric variables after 6 weeks of either high-dose MM
supplementation or placebo depending on HIV status.
Ethics approval and trial registration
Approval was obtained from the University of Zambia
Biomedical Research Ethics Committee (007-10-07). The
trial was registered as ISRCTN68751738.
Results
Patient groups and baseline characteristics
26 patients were randomised to placebo and 26 to MM
supplementation. Sections suitable for morphometric
analysis were available from 18/26 patients who received
MM supplementation and 20/26 patients who received
placebo, who all completed 6 weeks of supplement or
Figure 2 Example of morphometric analysis. Morphometry on a
jejunal biopsy demonstrating relatively mild features of EE, with
villous blunting and lymphocyte infiltration (arrows). H&E stained
sections at a magnification of x8 were digitised. Automatic threshold
definition was used to measure villous area (VA; area within blue
lines) and villous perimeter (VP; length of blue lines excluding base).
Villous height (VH; green), crypt depth (CD; cyan), maximal villous
width perpendicular to VH (VW; yellow), and muscularis mucosal
length (white; used as a denominator for VP and VA measurements)
were drawn by eye using the cursor on the computer monitor.
See also [2].
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placebo (Figure 3). 6/18 patients in the MM group and
9/20 patients in the placebo group were HIV positive
(P = 0.52, Fisher's exact test). Baseline characteristics
in MM and placebo groups were comparable (Table 2).
Effect of multiple micronutrient supplementation on
small bowel morphometry
In the 14 patients where both pre- and post-vaccination
data were available, results of analysis using post-vaccin-
ation measurements from these 14 patients were more
extreme in both magnitude and significance (Additional
file 2). The more conservative results using pre-vaccina-
tion measurements from these patients are therefore pre-
sented here.
In HIV negative patients given MM compared to pla-
cebo, mean VH was 24.0% greater (293.3 v. 236.6 μm;
mean difference 56.8 μm [95% confidence interval 17.7 –
95.9 μm]; P = 0.006, 2-tailed t test), mean VA per 100 μm
of mucosa was 27.6% greater (27623 v. 21650 μm2/
100 μm; mean difference 5973 μm2/100 μm [818 –
11130 μm2/100 μm]; P = 0.03, 2-tailed t test), and median
VP per 100 μm of mucosa was 29.7% greater (355.0 μm/
100 μm v. 273.7 μm/100 μm; median difference
81.3 μm/100 μm [16.3 – 146.2 μm/100 μm]; P = 0.003,
Kruskal-Wallis) (Figure 4). No significant differences were
observed in VW or CD. There were no changes in any
morphometric variables in HIV positive patients given
MM supplementation compared to placebo (Figure 5). As
a result of improved VH in HIV negative patients given
MM, villous:crypt (V:C) ratio was 1.56:1 with placebo v.
1.83:1 with MM (95% confidence interval of ratio follow-
ing treatment 1.63:1 – 2.03:1; P = 0.01, 2-tailed t test).
There was no significant difference in V:C ratio between
treatment groups in HIV positive patients.
VH, VP and VA were strongly positively correlated
with each other, particularly in HIV negative pa-
tients, with VP and VA having the strongest correl-
ation. There was no significant relationship between
crypt depth and any other variables in either group
(Tables 3 & 4).
Effect of Ty21a vaccination on morphometry
Adequately orientated biopsies before and after the
vaccination phase were available in 14 patients. This
subgroup was used to exclude an effect of vaccination
on small bowel architecture. In this group as a whole,
vaccination had no effect on any of the variables
measured (Figure 6). Furthermore, neither HIV status
nor treatment allocation influenced any of the measured
variables (Kruskal-Wallis).
Figure 3 CONSORT flow diagram.
Louis-Auguste et al. BMC Gastroenterology 2014, 14:15 Page 5 of 10
http://www.biomedcentral.com/1471-230X/14/15
Table 2 Patient baseline characteristics
Placebo MM P
Number 20 18
Mean (SD) age (years) 41.8 (10.5) 35.8 (11.0) 0.1j
Sex (male:female) 16:4 11:7 0.28k
HIV positive (number) 9 6 0.52k
CD4 count per μL (range) 159-656e 247-959h n/a
Median (IQR) Household Hygiene Scorea 5 (4.25-9.75) 5 (4.75-5) 0.34l
Never/rarely boil water (number) 15 13 1k
Never/rarely chlorinate water (number) 11 9 1m
BCG scar (number) 16 13 0.7k
Previous tuberculosis (number) 7 4 0.49m
Symptoms/signs of micronutrient deficiencyb 1 1 1k
Mean (SD) BMI (kg/m2) 23.7 (4.4) 24 (6.1) 0.84j
Mean (SD) MUAC (cm) 28.2 (5.5) 29.8 (6.7) 0.4j
Mean (SD) fat (%)c 37.1 (8.9)f 35.5 (10.5)i 0.64j
Mean (SD) water (%)c 46.9 (9.7)f 46.9 (8.2)i 1j
Mean (SD) dynamometry (kg)d 30.4 (6.0)g 31 (7.9)i 0.81j
Never/rarely drink alcohol (number) 14 9 0.32m
Median (IQR) approx. monthly income ($) 100 (60-120)f 80 (40-100)i 0.5n
Secondary education or better (number) 3 3 1m
Electricity supply (number) 4 5 0.71k
BMI, body mass index; MUAC, mid upper arm circumference. aThe Household Hygiene Score is an objective measure of the living conditions of each participant
and ranges from 0 (worst) to 10 (best). Trained fieldworkers score up to 2 points in each of five categories (overall cleanliness; water storage facilities; food
storage facilities; hand washing facilities and their use; sanitation facilities) [2]. bOne case of night blindness in both groups. cFat and water content was measured
using a Bodystat 1500 impedance analyser (Bodystat, Douglas, Isle of Mann). dDynamometry was measured using a Takeida dynamometer. eData available in 7/9
patients. fData available in 19/20 patients. gData available in 18/20 patients. hData available in 3/6 patients. iData available in 16/18 patients. j2-tailed t test. kFisher
exact test. lChi squared test for trend. mChi squared test. nKruskal-Wallis test.
Figure 4 Effect of MM in HIV negative patients. VH, VW, CD
measurements in μm; VP in μm/100 μm mucosa; VA in μm2/100 μm
mucosa x0.01 (rescaled for ease of presentation). VH, VA and CD:
2-tailed t test; VW and VP: Kruskal-Wallis.
Figure 5 Effect of MM in HIV positive patients. VH, VW, CD
measurements in μm; VP in μm/100 μm mucosa; VA in μm2/100 μm
mucosa x0.01 (rescaled for ease of presentation). VH, VA and CD:
2-tailed t test; VW and VP: Kruskal-Wallis.
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Safety
No serious adverse events were reported over the 6 week
supplementation period. Apart from patient-reported
cough in HIV negative patients receiving placebo, there
were no differences in adverse events between the two
intervention groups (Additional file 3: Figure S3). No
patient needed to discontinue the trial medication.
Clinical and immunological assessments of vaccine safety
have been reported elsewhere [22].
Discussion
Environmental enteropathy is a disorder which is
clinically silent. Emerging evidence suggests that it con-
tributes to poor responses to oral vaccines, to malab-
sorption of micronutrients and drugs, and to bacterial
translocation [1,4,6]. Several possible explanations have
been advanced for its aetiology, including subclinical
infections [2] and undernutrition. Here we present
evidence for the first time that a short term nutritional
intervention can significantly improve a cardinal feature
of the condition: namely, villous height and the absorptive
surface area of the small intestine. To our knowledge, this
is also the only interventional trial in environmental enter-
opathy which has directly assessed the intestinal mucosa;
other studies have used indirect measures of enteropathy
such as sugar absorption/permeability assays. Large scale
trials using histological assessment are unlikely given the
difficulty and technical expertise required to conduct
them. Therefore, the principal limitation of this study
is that only 38 participants were randomised to the
supplement or to placebo. Reduced compliance is unlikely
to have been a major issue over this short, intensive trial,
and our analysis was on an intention-to-treat basis.
We found that relatively high dose multiple micronu-
trient supplementation results in large and significant
changes in villous height, villous perimeter and villous
area in HIV negative patients. These are measures of
absorptive area and should reflect enhanced absorptive
capacity. Furthermore, our previous work confirmed a
negative correlation between villous height and intestinal
permeability in EE [2]; the histological improvements we
have observed should therefore also be associated with a
functional improvement. Future work will investigate this.
Interestingly, increased villous height following MM
supplementation was not associated with reduced crypt
depth; in other words mucosal thickness increased with
treatment. The enteropathies associated with coeliac
disease and graft-versus-host disease demonstrate a
negative correlation between crypt depth and villous
height, so that mucosal thickness remains relatively
constant. Animal and human experimental models of
various small intestinal enteropathies and observations of
human coeliac disease demonstrate a multiphasic mor-
phological and T cell-mediated immunological response:
an initial proliferative phase with increased crypt cell
proliferation and crypt hypertrophy, is followed by a
destructive phase characterised by villous atrophy [23-27].
Milder enteropathies are characterised by less marked T
cell activation responses and a less destructive phenotype
[24]; these processes are also postulated to occur in EE.
However, it is not clear to what extent these experiments
using acute T cell activation models are applicable to the
chronic, low grade inflammation seen in EE. But we are
tempted to speculate that villous and crypt morphology
Table 3 Correlations between measured variables: HIV
negative patients
Villous
height
Crypt
depth
Villous
perimeter
Villous
width
Villous
area
Villous height 1.000
Crypt depth 0.18 1.000
Villous perimeter 0.715** 0.18 1.000
Villous width 0.424* -0.11 0.14 1.000
Villous area 0.732** 0.17 0.796** 0.426* 1.000
2-tailed Spearman rho. *P < 0.05; **P < 0.001.
Table 4 Correlations between measured variables: HIV
positive patients
Villous
height
Crypt
depth
Villous
perimeter
Villous
width
Villous
area
Villous height 1.000
Crypt depth 0.254 1.000
Villous perimeter 0.514* -0.236 1.000
Villous width 0.182 0.182 -0.268 1.000
Villous area 0.511* -0.154 0.882** 0.093 1.000
2-tailed Spearman rho. *P < 0.05; **P < 0.001.
Figure 6 Immunisation with Vivotif vaccine had no effect on
any of the measured variables. VH, VW, CD measurements in μm;
VP in μm/100 μm mucosa; VA in μm2/100 μm mucosa x0.01
(rescaled for ease of presentation). n = 14. VH, VA and CD: paired
2-tailed t test; VW and VP: Wilcoxon signed rank.
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have different determinants, and it would appear that it is
mainly the villous compartment which can be influenced
by nutritional interventions.
Conversely, MM did not improve EE associated with
HIV enteropathy. We use the term ‘HIV enteropathy’
here to describe all mucosal remodelling processes in
patients who are HIV infected, the large majority of
whom are asymptomatic. Some other workers have used
the term ‘HIV enteropathy’ to refer only to patients with
apparently pathogen-negative persistent diarrhoea, but
we find this usage insufficiently specific.
It is possible that an effect on HIV enteropathy may
have been masked by the small number of patients in
this group. However, a post hoc power analysis suggests
that we should still have detected a change in morphom-
etry in HIV patients if MM resulted in a similar or
greater degree of improvement. Any histological impro-
vement, if present, would therefore be of a smaller
magnitude. The reduced or absent response of villous
architecture to our nutritional intervention in the pres-
ence of HIV suggests this is a distinct pathophysiological
condition, where HIV infection alters the sequelae of EE.
This is consistent with the mucosal changes we have
previously observed in asymptomatic HIV positive adults
living in impoverished environments in Lusaka [2]. We
believe that our use of the term ‘HIV enteropathy’ in this
context is therefore justified.
Observational data have suggested that micronutrient
deficiency is associated with worse prognosis in HIV
positive patients [17], providing a rationale for supple-
mentation. Patients with HIV also have an increased
incidence of micronutrient deficiency, which may reflect
increased malabsorption from a more severe enterop-
athy, dietary deficiency, and/or increased micronutrient
requirements/turnover from the underlying exaggerated
immune response. There is now some evidence that
multiple micronutrient supplements improve clinical
outcome in HIV positive adults and in sub-Saharan
Africa [12,19], but the mechanism underlying this im-
provement is unclear. Our data cannot exclude a small
improvement in absorptive area, which could underlie
the improvement. Finally, the influence of micronutrient
supplementation on outcomes of anti-retroviral therapy
(ART) remains unknown and is an area of intense
ongoing research. In Western patients at least, vitamin
D [28] and retinoic acid [29] levels appear to be de-
pressed by ART. Therefore, MM may be less efficacious
in HIV positive patients due both to the disease and/or
ART resulting in lower baseline micronutrient levels.
Unfortunately the small numbers of HIV positive pa-
tients in this study do not permit further analysis, and
we are aware of only four patients who were on ART at
the time of the study. Dedicated research to answer all
of these questions is ongoing.
One previous observational study has looked at small
bowel morphometry in the same patient population
(Additional file 4) [2]. Our measurements on the whole
correlate well with this previous study on HIV enterop-
athy and EE; we suspect that modifications to the algo-
rithm used to calculate villous area and villous perimeter
account for differences in these measurements in the
current study. In contrast to our previous study, we
could not confirm an effect of HIV on crypt depth. A
consistent finding in both of these studies is that total
mucosal thickness in HIV enteropathy and EE is similar.
Multiple micronutrient supplementation is seen by
many nutritionists as preferable to single nutrient supple-
mentation as it more closely approximates a balanced
intake. Single nutrient supplementation (e.g. zinc supple-
mentation for acute diarrhoea) is more of a pharmaco-
logical approach, whereas combined nutrient supplements
could be thought of as restoration of nutritional health. In
the supplement used in this trial, most micronutrients
were at doses of at least twice the recommended nutrient
intake, as previous work demonstrated that lower doses
did not reliably increase the concentrations of the micro-
nutrients in blood [12], possibly reflecting the very malab-
sorptive problem which we are trying to overcome. We
cannot say with confidence which nutrient might have
contributed most to the effect observed. Several nutrients
contained in the supplement could have effects on the
mucosal immune system and/or the microbiome (e.g.
vitamins A & D; zinc) [30-32]. Further work is needed to
determine if there is an optimal supplement composition.
Although pre-supplementation biopsies were not ob-
tained, the changes observed are most easily explained
by the supplement given, rather than by unidentified
differeces in the treatment arms at baseline. Firstly, EE is
virtually universal in this population [2,3]. Secondly,
randomisation was robust and both intervention groups
had similar baseline characteristics, particularly in mul-
tiple measures of hygiene, nutrition and socioeconomic
status. Furthermore, treatment allocation was carefully
masked by the manufacturer and the possibility that
some systematic bias might explain the differences
observed in HIV negative patients seems low. Thirdly,
morphometric measurements (with and without HIV)
from our patients given placebo are similar to those
from our previous study, which studied the same patient
population (Additional file 4) [2]. Therefore, the two
groups were homogeneous at baseline and it is unlikely
that the changes observed could be due to chance pre-
intervention differences between the patient groups.
Similarly, we found no effect of vaccination on morph-
ometry. We therefore included these measurements so
that we were able to analyse an almost complete data
set. Again, a small effect of vaccination on morphometry
may have been masked by the small sample size, but we
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think this is unlikely. Firstly, our results were significant
with datasets using either pre- or post-vaccination data.
Secondly, the lack of vaccine effect on upper small intes-
tinal morphometry is consistent with the predilection of
S. Typhi for the Peyer patches of the distal ileum.
Finally, histological analysis of enteric fever in humans
has confirmed that proximal small bowel morphometry
is unaffected in the course of illness [33].
Conclusions
Approximately 2 billion people in the developing world
live in conditions where safe water is difficult to obtain,
food is neither secure nor diverse, and sanitation is sub-
optimal. These populations have a high prevalence of
environmental enteropathy. Our data suggest that high
dose MM may provide an effective and affordable treat-
ment option to reverse the histological abnormalities
observed in EE in HIV negative patients, which will hope-
fully result in enhanced intestinal absorption, permeability,
and perhaps even vaccine responses. Larger randomised
controlled trials with physiological and clinical endpoints
are therefore urgently needed.
Additional files
Additional file 1: Macro used for morphometric analysis.
Additional file 2: Comparison of significant results in HIV negative
patients, using either pre- or post-vaccination datasets. Comparison
of significant results in HIV negative patients, using a dataset including
either pre- or post-vaccination data in 14/38 patients where data was
available for both time points. Results show differences and P values
comparing HIV negative patients given MM versus placebo. There
remained no significant differences in crypt depth or villous width, or in
any variables in HIV positive patients. MM, multiple micronutrient
supplementation; VA, villous area; VH, villous height; VP, villous perimeter.
Additional file 3: Adverse events during period of supplementation.
aP values given for Fisher's exact test. bSevere diarrhoea defined as diarrhoea
resulting in time off work or usual activities, use of antibiotics,
use of oral rehydration solution, or healthcare assessment (there were no
hospitalisations). MM, multiple micronutrient supplementation.
Additional file 4: Comparison of morphometric studies of EE and/or
HIV enteropathy in Zambian adults. *Significant difference (P <0.05)
between patient groups. Mucosal thickness in the Kelly study was not
stated and has been calculated by adding mean VH and CD. VH, CD, VW
and MT expressed in μm (SD; IQR for VW in current study); VA and VP
expressed in μm/100 μm mucosal length (SD; IQR for VA in current
study). CD, crypt depth; EE, environmental enteropathy; IQR, interquartile
range; MM, multiple micronutrient supplementation; MT, mucosal
thickness; VA, villous area; VH, villous height; VP, villous perimeter;
VW, villous width.
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